Baxter International Inc.  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
69.66
-1.22 (-1.72%)
Jun 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 69.66 - 71.04
52 week 50.61 - 73.95
Open 70.69
Vol / Avg. 2.11M/3.99M
Mkt cap 37.75B
P/E 16.81
Div/yield 0.49/2.81
EPS 4.14
Shares 541.95M
Beta 0.51
Inst. own 84%
Jul 15, 2013
Q2 2013 Baxter International Inc. Earnings Release Add to calendar
Jun 11, 2013
Baxter International Inc. at Goldman Sachs Healthcare Conference - Webcast
May 29, 2013
Baxter International Inc. at Deutsche Bank dbAccess Health Care Conference - Webcast
May 14, 2013
Baxter International Inc. at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2013
Baxter International Inc. Annual Shareholder Meeting - Webcast
May 7, 2013
Baxter International Inc. Conference Call to Discuss Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease - Webcast
Apr 18, 2013
Q1 2013 Baxter International Inc. Earnings Conference Call - Webcast
Apr 16, 2013
Q1 2013 Baxter International Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 16.01% 16.39%
Operating margin 20.01% 20.36%
EBITD margin - 28.56%
Return on average assets 10.88% 11.79%
Return on average equity 31.86% 34.40%
Employees 51,000 -
Carbon Disclosure Rating - 77/100

Address

One Baxter Parkway
DEERFIELD, IL 60015-4625
United States - Map
+1-800-4229837 (Phone)
+1-800-5685020 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia
Discussion Group - Google Finance

Description

Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors� offices, clinical and medical research laboratories, and by patients at home under physician supervision. In February 2012, it acquired Synovis Life Technologies, Inc. In November 2011, it acquired Baxa Corporation. In April 2012, it purchased SIGMA International General Medical Apparatus, LLC.

Officers and directors

Robert L. Parkinson Jr. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Robert J. Hombach CPA Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Sebastian J. Bufalino Corporate Vice President, Controller
Age: 52
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Phillip L. Batchelor Corporate Vice President - Quality and Regulatory Affairs
Age: 51
Bio & Compensation  - Reuters
Jean-Luc Butel Corporate Vice President, President - International
Age: 56
Bio & Compensation  - Reuters
Robert M. Davis Corporate Vice President, President - Medical Products
Age: 46
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Corporate Vice President, President - BioScience
Age: 50
Bio & Compensation  - Reuters
Peter S. Hellman Lead Independent Director
Age: 63
Bio & Compensation  - Reuters